Cochran A J, Todd G, Hart D M, Morrison L J, MacKie R M
Department of Surgery, UCLA School of Medicine, Los Angeles, CA 90024.
Cancer Immunol Immunother. 1982;14(2):78-81. doi: 10.1007/BF00200171.
Using a one-stage capillary leukocyte migration inhibition assay, we examined peripheral blood leukocytes from 97 patients with malignant melanoma, 194 pregnant women, and 123 non-pregnant donors for their reactivity with materials from fetal and melanomatous tissues. As in previous studies, we found melanoma extracts selectively to inhibit melanoma patients' leukocytes. First-trimester fetal extracts also selectively inhibited melanoma patients' leukocytes, suggesting their cross-reactivity with melanoma-derived antigens. We could not localize the source of the inhibitory materials within the fetuses. We found no evidence that pregnant women were selectively immunized to fetal or melanoma extracts, regardless of their parity or the stage of their pregnancy.
我们采用单阶段毛细管白细胞迁移抑制试验,检测了97例恶性黑色素瘤患者、194例孕妇和123例非孕供血者的外周血白细胞对来自胎儿组织和黑色素瘤组织的物质的反应性。与之前的研究一样,我们发现黑色素瘤提取物能选择性地抑制黑色素瘤患者的白细胞。孕早期胎儿提取物也能选择性地抑制黑色素瘤患者的白细胞,提示它们与黑色素瘤衍生抗原有交叉反应性。我们无法确定胎儿体内抑制物质的来源。我们没有发现证据表明孕妇会被胎儿提取物或黑色素瘤提取物选择性免疫,无论其生育史或妊娠阶段如何。